Fig. 3From: Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohort studyThe relative dose intensity of oxaliplatin (RDI-O) ≥60 vs < 60% and early recurrence in low-risk (a) and high-risk (b) subgroups within 12, 18 and 36 monthsBack to article page